Cardiovascular manifestations of substance abuse: part 2: alcohol, amphetamines, heroin, cannabis, and caffeine.
about
Potential adverse effects of amphetamine treatment on brain and behavior: a reviewAt the bottom of the differential diagnosis list: unusual causes of pediatric hypertensionKinetic and cardiovascular effects of acute topiramate dosing among non-treatment-seeking, methamphetamine-dependent individuals.Ventricular fibrillation triggered by marijuana use in a patient with ischemic cardiomyopathy: a case report.Energy beverages: content and safety.Single ryanodine receptor channel basis of caffeine's action on Ca2+ sparksIdentifying patients with problematic drug use in the emergency department: results of a multisite study.Interaction effects of age and contingency management treatments in cocaine-dependent outpatients.Cardiovascular risk factors and 30-year cardiovascular risk in homeless adults with mental illnessThe Medicinal Cannabis Treatment Agreement: Providing Information to Chronic Pain Patients Through a Written Document.The Effects of Opioid Substitution Treatment and Highly Active Antiretroviral Therapy on the Cause-Specific Risk of Mortality Among HIV-Positive People Who Inject DrugsEndothelial Nitric Oxide Mediates Caffeine Antagonism of Alcohol-Induced Cerebral Artery Constriction.Older methadone patients achieve greater durations of cocaine abstinence with contingency management than younger patients.Drugs of abuse and the aging brain.Exercise stress testing in recently abstinent chronic cocaine abusers.Clinical factors associated with early readmission among acutely decompensated heart failure patientsMetabolic syndrome in drug abuse.Micromorphological changes in cardiac tissue of drug-related deaths with emphasis on chronic illicit opioid abuse.CVD risk among men participating in the National Health and Nutrition Examination Survey (NHANES) from 2001 to 2010: differences by sexual minority statusManaging young people with Type 1 diabetes in a 'rave' new world: metabolic complications of substance abuse in Type 1 diabetes.Corticotropin-releasing factor (CRF) receptor-1 is involved in cardiac noradrenergic activity observed during naloxone-precipitated morphine withdrawalFactors Influencing the Frequency of Emergency Department Utilization by Individuals with Substance Use Disorders.Cardiovascular Disease Mortality of Medicaid Clients with Severe Mental Illness and a Co-occurring Substance Use Disorder.Relationship between marijuana and other illicit drug use and depression/suicidal thoughts among late middle-aged and older adults.Risk factors for encephalitis and death from West Nile virus infection.Early use of beta blockers in patients with cocaine associated chest pain.Neurological abnormalities in opiate addicts with and without substitution therapy.Effect of acute marijuana on cardiovascular function and central nervous system pharmacokinetics of [(15)O]water: effect in occasional and chronic users.Effect of amphetamine on corrected-QT interval change during methadone maintenance treatment in Taiwan: a prospective cohort study.A linkage analysis of cigarette and alcohol consumption in an unselected Mexican American population.Histological findings of the atrioventricular conductive system in street heroin addicts, victims of sudden unexpected death.Trends related to aging and co-occurring disorders in HIV-infected drug users.Natural approaches in metabolic syndrome management.Role of toxicological determinations of amphetamines and cannabinoids in hair of adolescent patients in cardiologic diagnostic management.Identifying and Addressing the Unmet Health Care Needs of Drug Court Clients.Comorbidities and Consequences in Hospitalized Heart Failure Patients with Depression
P2860
Q24657966-E11EB164-E452-4B3D-B5B5-6EFE78AA1000Q30438226-30D4B703-7605-4C7A-88A8-F9D75014AA2DQ30442417-505ADDCB-99ED-4262-8402-9BF8A7D476ACQ33156879-C6227B6F-C4A8-4E63-839F-3E4A55D21F34Q34252431-22537C4F-5C35-49CF-B4A3-DB1AC5645F70Q34568146-4C423666-AF27-41BC-9B4E-CC395EA7D918Q34616353-F23C0017-9998-4814-97F8-0009F083DB6DQ35062387-4947D786-D2E3-4497-8C58-71B41316E535Q35118808-A9A35983-1AEC-4446-BD8F-74E82890202BQ35563620-1535B11F-143D-4242-9DFC-A5890F53A04CQ36030512-E24E3360-F3CB-43D2-9D4F-6D3792B2183BQ36432315-CC44B28A-6CF2-4EDE-B94F-A97780EE5ABCQ36626995-EA17AF9F-54CD-4CB5-B5E1-C0AEC6045268Q36779439-36EADE98-8AE1-4173-BDE3-99B3E65381B3Q36924616-CDA95ED8-F5FA-42AD-B5CE-F2D9E24AC186Q36958272-51688FBC-65EB-4B12-A97E-C6558DA2DDF2Q37031208-D1FD2CBC-ABE8-4489-B0CE-51FFE1959A68Q37101668-AC2D1D1A-3C0A-4C79-A566-72BDFB5FEBECQ37331653-47AA0DB9-562E-435C-8169-90B8DD3FCA99Q37457038-FCF5B69C-ECE2-4F13-9744-22DE13366172Q37671294-90A6366D-9173-4AD3-80DC-14DCFF1480ADQ39998419-FD6C8FED-C5F2-4E95-AFDA-24A331F523E6Q39998544-97BBD0DF-6E3A-4461-8213-4A7404582A88Q40350263-1D81AC01-C04C-4775-B52B-CD3C89D3A7E4Q40479908-04436BED-50BF-44CA-83E9-D09ED50D4BFCQ40963776-78BA6801-76F7-4B35-BF89-683A56FCFAB6Q44138865-987391F7-B6D7-423D-BE1C-2FCAD2B348CBQ44938167-7BC4BD77-2426-4FB0-8329-C50ADC198D9DQ45935213-BF54AC6A-65B0-43C5-B96C-70FFEBD8EC87Q46830127-E3128668-126B-453C-9080-7B58251E710AQ48329053-5D58440A-F54B-4797-9E2D-40FD63D22631Q48915551-5A7B7EC2-756B-4F6E-BB94-FD2B65A716B0Q51758644-4D1D1F7D-656D-4E7A-AB02-687D3072CCD2Q52298981-83A4385C-BF75-4247-A166-1ECC06C94ED2Q53754568-AFD8D7FA-9020-40B8-AE68-404B507C095AQ58564613-A040DD25-13D6-40AB-BDBB-90476B56D615
P2860
Cardiovascular manifestations of substance abuse: part 2: alcohol, amphetamines, heroin, cannabis, and caffeine.
description
2003 nî lūn-bûn
@nan
2003 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Cardiovascular manifestations ...... eroin, cannabis, and caffeine.
@ast
Cardiovascular manifestations ...... eroin, cannabis, and caffeine.
@en
type
label
Cardiovascular manifestations ...... eroin, cannabis, and caffeine.
@ast
Cardiovascular manifestations ...... eroin, cannabis, and caffeine.
@en
prefLabel
Cardiovascular manifestations ...... eroin, cannabis, and caffeine.
@ast
Cardiovascular manifestations ...... eroin, cannabis, and caffeine.
@en
P2093
P1476
Cardiovascular manifestations ...... eroin, cannabis, and caffeine.
@en
P2093
Alexander Del Vecchio
Anjum Ismail
Shirin Sanal
William H Frishman
P304
P356
10.1097/01.HDX.0000080713.09303.A6
P577
2003-07-01T00:00:00Z